Onxeo S.A.: Judith Greciet, invited as guest speaker at international Allicense Conference

May 5-6, 2015 – San Francisco, CA
PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE (http://www.businesswire.com/))--
Regulatory News:

Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ Copenhagen:
ONXEO), an innovative company specializing in the development of orphan oncology
drugs, today announced that Judith Greciet, CEO of Onxeo, has been invited to
participate to the 2015 Allicense Conference as a panelist for the session
entitled “Eat or Be Eaten—The Specialty Pharma Survival Story”.

As one of the active deal-making organizations during the last months,
especially with the last year’s acquisition and merger of TopoTarget by
BioAlliance Pharma, Onxeo is a particularly compelling story, and certainly
unique among mid-size European-based biotechs. Judith Greciet will contribute as
a player and a witness to this very timely topic, with the recent Onxeo’s story
of increasing size and critical mass through a merger in order to emerge as new
global playor in the orphan oncology drugs area.

Allicense Conference brings together professionals from the Pharma, Biotech and
Financial communities. It offers opportunities for exchange of information and
debate, especially in dealmaking, licensing and business development areas.

The conference takes place on May 5 and 6 (the session “Eat or Be Eaten—The
Specialty Pharma Survival Story” is on the 6th at 2:15pm) at the Park Central
Hotel in San Francisco.

About Allicense

The Allicense Conference is the leading event for dealmaking, licensing and
business development professionals, and is hosted by Thomson Reuters, the
leading provider of intelligence for the life sciences Business Development and
Licensing market.

About Onxeo

Onxeo has the vision to become a global leader and pioneer in oncology, with a
focus on orphan or rare cancers, through developing innovative therapeutic
alternatives designed to “make the difference”. The Onxeo team is determined to
develop innovative medicines that provide patients with hope and significantly
improve their lives.

Key orphan oncology products at the advanced development stage are:
Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma
Validive® (Clonidine Lauriad®): Phase II in severe oral mucositis: Positive
preliminary top-line results
Beleodaq® (belinostat): registered in the US in peripheral T-cell lymphoma

For more information, visit the
website www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3
A 
%2F%2Fwww.onxeo.com&esheet=51070312&newsitemid=0&lan=en
-US&anchor=www.onxeo.com&index=1&md5=81c24d9b7d6921c36891494a0368168c)

Disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Onxeo and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors, which could cause the
actual results, financial condition, performance or achievements of Onxeo to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Onxeo is providing this
communication as of this date and does not undertake to update any forward
-looking statements contained herein as a result of new information, future
events or otherwise. For a discussion of risks and uncertainties which could
cause actual results, financial condition, performance or achievements of Onxeo
to differ from those contained in the forward-looking statements, please refer
to the Risk Factors ("Facteurs de Risque") section of the 2013 Reference
Document filed with the AMF on April 7, 2014, which is available on the AMF
website (http://www.amf
-france.org (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww
. 
amf-france.org&esheet=51070312&newsitemid=0&lan=en
-US&anchor=http%3A%2F%2Fwww.amf
-france.org&index=2&md5=e9641d17b79ed3afc0163871bed2657e)) or on the company’s
website
(www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2F
w 
ww.onxeo.com&esheet=51070312&newsitemid=0&lan=en
-US&anchor=www.onxeo.com&index=3&md5=7b5debad1a52b796ec1abec1b35b972a)).
Onxeo S.A.
Judith Greciet, CEO
j.greciet@onxeo.com
or
Nicolas Fellmann, CFO
n.fellmann@onxeo.com
+33 1 45 58 76 00
or
Alize RP
Caroline Carmagnol / Sophie Colin, +33 6 64 18 99 59 / +33 1 44 54 36 62
onxeo@alizerp.com